Comparison of two calcium blockers on hemodynamics, left ventricular mass, and coronary vasodilatory in advanced

J A Diamond1, L R Krakoff, A Goldman

  • 1Section of Hypertension & Nuclear Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, the Mount Sinai Medical Center, New York, New York 10029-6574, USA. joseph.diamond@mssm.edu

Insights

Both nifedipine-GITS and verapamil-SR effectively lower blood pressure in hypertension. While both calcium channel blockers (CCB) reduce blood pressure and left ventricular mass, they show distinct effects on heart rate and neurohormonal responses.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dihydropyridine and nondihydropyridine calcium channel blockers (CCB) possess distinct pharmacologic properties.
  • Limited clinical data exists comparing CCB efficacy as monotherapy.

Purpose of the Study:

  • To conduct a comprehensive comparison of nifedipine-GITS and verapamil-SR in patients with moderate to severe hypertension.
  • To evaluate differences in hemodynamic profiles, neurohormonal responses, and clinical outcomes.

Main Methods:

  • Thirty patients with diastolic blood pressure >= 100 mm Hg were randomized to nifedipine-GITS or verapamil-SR.
  • Dose titration aimed for diastolic blood pressure <= 95 mm Hg or a >= 15 mm Hg decrease over 4 weeks.
  • Assessments included clinic BP, 24-h ambulatory BP, exercise BP, echocardiography, coronary flow reserve, and plasma biomarkers.

Main Results:

  • Both drugs similarly reduced clinic and 24-h ambulatory blood pressure and left ventricular mass index.
  • Verapamil-SR significantly lowered resting and peak exercise heart rate compared to nifedipine-GITS.
  • Nifedipine-GITS showed a lower peak exercise systolic BP and transiently reduced atrial natriuretic peptide; verapamil-SR lowered norepinephrine.
  • No significant differences were observed in left ventricular function or coronary flow reserve.

Conclusions:

  • Once-daily nifedipine-GITS and verapamil-SR are equally effective in reducing arterial pressure in moderate to severe hypertension.
  • Observed differences in hemodynamic and neurohormonal responses align with their known preclinical pharmacologic profiles.
  • Further outcome studies are needed to fully elucidate the clinical implications of these similarities and differences.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...